# " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

> **NCT05580510** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Instituto Nacional de Cardiologia Ignacio Chavez** · enrollment: 160 (estimated)

## Conditions studied

- Congenital Heart Disease
- Heart Failure
- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
- **DRUG:** Empagliflozin 10 MG OD

## Key facts

- **NCT ID:** NCT05580510
- **Lead sponsor:** Instituto Nacional de Cardiologia Ignacio Chavez
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-06
- **Primary completion:** 2023-07-28
- **Final completion:** 2024-03-29
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2022-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05580510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05580510, "" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05580510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*